MK-677 (Ibutamoren) Compounding Pharmacy: How to Read a Certificate of Analysis

What MK-677 (Ibutamoren) Is and Why Sourcing Matters

MK-677 is an orally active, selective ghrelin receptor agonist that stimulates pulsatile growth hormone secretion and raises circulating IGF-1 without suppressing endogenous GH production. Because the FDA has not approved it as a finished drug product, every commercially available dose exists either as a research chemical or as a compounded preparation.

Pharmacological Profile in Brief

In a 2-year randomized controlled trial (N=65), oral MK-677 25 mg daily increased serum IGF-1 by 39.9% above baseline in healthy older adults and improved lean body mass 1. A separate 12-month trial (N=123) in adults with hip fracture showed MK-677 25 mg daily raised IGF-1 by 84% and reduced the number of falls compared with placebo 2. Both trials used pharmaceutical-grade compound with verified purity. That distinction matters. If the purity of a batch deviates even modestly, the dose-response relationship described in these trials no longer applies.

The Research Chemical vs. Compounded Drug Distinction

Research chemicals are sold explicitly for laboratory use only, are not subject to pharmaceutical manufacturing standards, and are not legal for human consumption under the Federal Food, Drug, and Cosmetic Act 3. Compounded MK-677 prepared by a licensed 503A pharmacy under a patient-specific prescription occupies a different regulatory position, though the FDA has flagged compounded growth hormone secretagogues in enforcement communications 4. The COA is your primary tool for distinguishing one from the other.

Regulatory Framework Governing Compounded MK-677

Compounding pharmacies operate under a layered framework that includes federal statute, FDA oversight, USP standards, and individual state board rules.

Federal Statutes: FDCA and the Drug Quality and Security Act

The Drug Quality and Security Act of 2013 (DSCSA) created two categories of compounders: 503A pharmacies (patient-specific, physician-prescribed) and 503B outsourcing facilities (bulk, FDA-registered). A 503A pharmacy may compound MK-677 only on receipt of a valid prescription and may not compound it in anticipation of prescriptions at the scale a 503B facility can 5. The FDA's current position is that MK-677 is not an approved drug and appears on no FDA bulk drug substances list cleared for compounding under 503A or 503B provisions, which creates meaningful legal exposure for pharmacies that compound it 3.

USP <795> and USP <797>: What Each Requires

USP <795> governs non-sterile preparations (capsules, oral solutions). It sets requirements for beyond-use dating, environmental monitoring, personnel training, and container-closure integrity 6. USP <797> governs sterile preparations (injections). Sterile compounded MK-677 would be subject to stricter controls: ISO-classified cleanrooms, sterility testing per USP <71>, bacterial endotoxin testing per USP <85>, and particulate matter limits per USP <788> 7.

State boards of pharmacy enforce these chapters locally and may adopt additional requirements. California, for example, requires PCAB accreditation for a pharmacy to market itself as a compounding specialty pharmacy. Confirming your pharmacy's board license status takes under two minutes on most state board websites.

PCAB Accreditation and What It Signals

PCAB (Pharmacy Compounding Accreditation Board) accreditation is a voluntary third-party audit that examines facilities, personnel competencies, SOPs, and quality systems. Fewer than 350 pharmacies in the United States hold PCAB accreditation as of 2025. Accreditation does not mean the FDA has approved any specific compound, but it does mean an independent auditor has verified that the pharmacy follows defined quality systems. A COA from a PCAB-accredited pharmacy carries more evidentiary weight than one from an unaccredited source.

How to Read an MK-677 Certificate of Analysis: Line by Line

A legitimate COA is a structured document issued by an independent, accredited analytical laboratory. "Independent" means the lab conducting testing is not owned by the compounding pharmacy or the raw-material supplier.

Section 1: Identity and Lot Traceability

The first block of a COA should contain:

• Product name and CAS number. MK-677 (Ibutamoren mesylate) carries CAS 159634-47-6.
• Lot or batch number that matches the label on your dispensed product.
• Manufacturer or raw-material supplier name.
• Date of manufacture and testing date.
• Quantity tested (in grams or milligrams).

If the lot number on your dispensed capsule bottle does not match the lot number on the COA, the document is not valid for your specific product. This mismatch is one of the most common COA fraud patterns the FDA has documented in warning letters to compounders 4.

Section 2: HPLC Purity and Identity Confirmation

High-performance liquid chromatography (HPLC) is the gold standard for purity determination. The COA should report:

• Purity by HPLC: Minimum 98.0% for pharmaceutical compounding. Values below 95% indicate a research-grade or degraded material not suitable for human use.
• Related substances (impurities): Each individual unknown impurity should be <0.5%, and total impurities should be <2.0%.
• Retention time match: The HPLC chromatogram should show a retention time consistent with a certified MK-677 reference standard.

Nuclear magnetic resonance (NMR) spectroscopy adds a second identity confirmation layer. Some accredited labs include both HPLC and NMR; a COA with both is more defensible than one with HPLC alone. Mass spectrometry (LC-MS/MS) can confirm molecular weight of 624.78 g/mol for ibutamoren mesylate, providing a third identity check 8.

Section 3: Endotoxin Testing

Endotoxin testing is required for sterile injectable preparations under USP <85>, using the Limulus Amebocyte Lysate (LAL) assay. For compounded MK-677 presented as oral capsules, endotoxin testing is not a USP <795> requirement because the oral route does not present the same systemic endotoxin risk as intravenous or subcutaneous delivery.

If a pharmacy is compounding injectable MK-677 (an off-label sterile preparation), the COA must show endotoxin <5 EU/mg. Any sterile preparation lacking an endotoxin result on its COA is missing a mandatory test 7.

Section 4: Residual Solvents

The raw active pharmaceutical ingredient (API) is synthesized using organic solvents. USP <467> classifies solvents by toxicity class. Class 1 solvents (benzene, carbon tetrachloride) should be absent. Class 2 solvents (acetonitrile, methanol, dichloromethane) each carry specific limits in parts per million. A COA should list each detected solvent by name and its measured concentration against the USP <467> limit 9.

Section 5: Microbial Limits (Non-Sterile)

For oral MK-677 capsules, USP <795> and USP <2021> define microbial limits for total aerobic microbial count (TAMC) and total yeast and mold count (TYMC). Acceptable limits for oral solid dosage forms are TAMC <1,000 CFU/g and TYMC <100 CFU/g. Absence of specified organisms (Salmonella, E. Coli, Staphylococcus aureus) must also be confirmed.

Section 6: Heavy Metals

USP <232> and <233> set elemental impurity limits. Lead, arsenic, cadmium, and mercury are the four elements of primary concern. A COA that omits elemental impurity data should prompt a direct question to the pharmacy before accepting the preparation.

The HealthRX COA Scorecard for MK-677

When a pharmacist or clinician is evaluating an MK-677 COA, every line item can be assigned a pass, flag, or fail status. The following framework synthesizes USP chapter requirements, FDA guidance, and published analytical standards into a single decision tool.

| COA Line Item | Pass | Flag | Fail | |---|---|---|---| | HPLC Purity | >98.0% | 95.0-97.9% | <95.0% | | Individual impurity | <0.5% | 0.5-1.0% | >1.0% | | NMR/MS identity | Confirmed | Not performed | Contradicts HPLC | | Endotoxin (sterile only) | <5 EU/mg | 5-10 EU/mg | >10 EU/mg | | TAMC (oral) | <1,000 CFU/g | 1,000-5,000 CFU/g | >5,000 CFU/g | | Residual solvents | All within USP <467> limits | One Class 2 near limit | Any Class 1 detected | | Heavy metals | All within USP <232> | One element at 80-100% of limit | Any element over limit | | Lab accreditation | ISO 17025 | State-licensed only | No stated accreditation | | Lot number matches label | Yes | Partial match | No match |

A single "Fail" result on any row means the batch should be rejected without exception. Two or more "Flag" results should trigger a request for retesting before dispensing.

Where to Buy MK-677 and What Legal Status Means Practically

MK-677 is not scheduled under the Controlled Substances Act, which means simple possession is not a federal criminal offense. However, marketing it for human use without an FDA-approved new drug application violates the FDCA 3. Practically, this means:

• A licensed 503A pharmacy may prepare MK-677 with a valid patient-specific prescription from a licensed prescriber.
• A 503B outsourcing facility may not legally include MK-677 in its formulary without FDA bulk drug substance authorization, which has not been granted.
• "Research chemical" suppliers selling MK-677 labeled for laboratory use only operate outside pharmaceutical law entirely.

The FDA issued a Safety Communication in 2023 warning consumers about compounded peptide products making unsubstantiated efficacy claims 10. That document does not specifically name MK-677, but it covers the secretagogue class broadly. Any pharmacy claiming its MK-677 is FDA-approved is making a false statement.

Evaluating a Pharmacy Before Ordering

Before requesting a prescription from a telehealth provider that works with a specific compounding pharmacy, verify these five items:

1. The pharmacy holds a valid state board license in the state where it is physically located. Check the state board website directly, not the pharmacy's self-reported claims.
2. The pharmacy holds PCAB accreditation. Verify at pcab.pharmacy, the official PCAB registry.
3. The pharmacy provides COAs from an ISO 17025-accredited third-party laboratory. ISO 17025 is the international standard for analytical testing laboratory competence 11.
4. The pharmacy's COAs include lot-specific testing, not just API testing from the raw material supplier.
5. The pharmacy will share the full COA (not a summary) before dispensing upon patient or prescriber request.

Red Flags That Indicate Non-Pharmaceutical Sources

Research chemical suppliers frequently publish COAs that look legitimate but fail on close reading. Common problems the FDA has identified in warning letters include:

• COAs dated before the stated manufacturing date.
• Purity expressed as "99%+" without a chromatogram or method description.
• Lab names that do not appear in any ISO 17025 accreditation database.
• No lot number or a generic lot number used across multiple products 4.

The FDA maintains a searchable warning letter database. Searching "peptide" or "growth hormone secretagogue" in that database returns enforcement actions against multiple online suppliers whose COA practices were found materially deficient.

Clinical Context: Why Purity Affects Outcomes

The dose-response relationship for MK-677 is well characterized in the published literature. At 25 mg daily, the increase in GH pulse amplitude and IGF-1 is consistent and reproducible when pharmaceutical-grade compound is used 1. At lower purity levels, the actual delivered dose of active compound drops proportionally. A 95% pure product at a labeled dose of 25 mg delivers approximately 23.75 mg of active compound along with up to 1.25 mg of unknown impurities.

Impurity Risk Is Not Zero

Synthetic impurities from MK-677 manufacturing include process-related byproducts that have not been individually characterized for toxicity in humans. The FDA requires impurity qualification under ICH Q3A guidelines when individual impurities exceed 0.15% in a pharmaceutical drug product 12. Compounders are not formally subject to ICH Q3A, but applying that threshold as a practical standard is defensible clinical practice.

The IGF-1 Monitoring Connection

Because MK-677's primary measurable effect is IGF-1 elevation, serial IGF-1 measurements serve as an in-vivo purity proxy. If a patient takes 25 mg daily of a preparation claiming 99% purity and IGF-1 does not rise within the range documented in clinical trials (roughly 40 to 84% above baseline depending on baseline age and IGF-1 level), the most likely explanation is subtherapeutic active compound content, meaning the COA was inaccurate or fraudulent 2.

A baseline IGF-1 drawn before starting therapy and a follow-up drawn at 8 weeks on a stable dose gives the prescribing clinician a functional potency check that no COA can replace.

Sterility Testing: When It Applies to MK-677

MK-677 is orally bioavailable. Compounding it as a capsule or oral solution is the most common clinical format, and oral preparations are governed by USP <795>, not USP <797>. Sterility testing (USP <71>) applies only to sterile preparations.

Some clinicians and patients seek injectable MK-677. The published pharmacokinetic data does not support a clinical advantage for the injectable route given near-complete oral bioavailability demonstrated in early-phase trials 8. A pharmacy compounding injectable MK-677 takes on the full sterility burden of USP <797>: cleanroom qualification, media fill testing, sterility testing per USP <71>, and endotoxin testing per USP <85>. The COA for a sterile preparation should be substantially longer and more detailed than one for an oral capsule.

If a pharmacy offers injectable MK-677 with a COA that looks identical in length and complexity to one for an oral capsule, that is a strong signal that the sterility testing requirements are not being met.

How to Verify the Testing Laboratory on a COA

ISO 17025 accreditation for analytical laboratories is granted by accreditation bodies recognized by ILAC (International Laboratory Accreditation Cooperation). In the United States, the two primary ILAC-recognized accreditation bodies are A2LA (American Association for Laboratory Accreditation) and NVLAP (National Voluntary Laboratory Accreditation Program). Both maintain public searchable databases.

Steps to verify:

1. Identify the lab name and address on the COA.
2. Go to a2la.org or nist.gov/nvlap and use the directory search.
3. Confirm the lab's scope of accreditation includes the specific test methods cited on the COA (HPLC purity, LAL endotoxin, USP <71> sterility, etc.).
4. Confirm the accreditation was active on the date the COA was issued 11.

A lab whose accreditation expired three months before the COA was signed fails this check. Expired accreditation is not a minor administrative issue; it means the lab's measurement quality was not under external audit at the time of testing.